N/A N=170 Real World Data on Management of Male LUTS
Benign Prostatic Hyperplasia
Primary: The Percentage of Men Given a Drug Prescription for Their Urinary Symptoms, as Recorded in Their Medical Records — 35.7 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=10 Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms
Lower Urinary Tract Symptoms
Primary: Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.3/Wk12 — -10.9 pg/ml
N/A N=12 Urodynamic Feasibility Study Utilizing the UroLift® System
Benign Prostatic Hyperplasia
Primary: Qmax Assessed Using Urodynamic Testing (Cystometry) — 14.0 mL/sec
Phase 4 N=46 Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Benign Prostatic Hyperplasia (BPH)
Primary: Post-void Residual (PVR) Volume — 101.7; 75.8 mL
Phase 2 N=222 Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax) — -1.69; -7.84; -6.69 cmH2O
Phase 4 N=395 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Bladder Outlet Obstruction
Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants
N/A N=56 Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Urethral Sphincter Activity
Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05
Phase 4 N=232 The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
BPH
Primary: Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment — 13.0; 12.0; 10.6; 13.4 score — p=<0.05
Phase 2 N=200 A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax) — -0.33; 0.07; 0.30 mL/sec
N/A N=27 The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
Overactive Bladder
Primary: Change in the Relative Abundance of Lactobacillus — 0.143 proportion of total microbes
Phase 3 N=1,066 Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Lower Urinary Tract Symptoms · Benign Prostatic Hyperplasia
Primary: Number of Participants With Adverse Events (AEs) — 499; 255; 12; 69 participants
Phase 2 N=404 A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
Lower Urinary Tract Symptoms (LUTS)
Primary: Mean Change in International Prostate Symptom Score (IPSS) — -4.46; -5.65; -6.11; -5.88 percentage change from baseline — p=0.0911
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Phase 3 N=1,334 Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptoms
Primary: Change From Baseline to End of Treatment in Total International Prostate Symptom Score — -5.4; -6.2; -7.0; -6.5 units on a scale — p=0.001
N/A N=463 Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
Urinary Incontinence, Stress · Urinary Incontinence, Urge
Primary: Group Behavioral Treatment Effectiveness as Shown by Changes From Baseline to 3 Months in Urinary Incontinence Severity. — -2; -1 units on a scale
Phase 4 N=715 A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia · Overactive Bladder
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per Day — -2.00; -1.62 micturitions per day — p=0.039
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
N/A N=206 The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Benign Prostatic Hyperplasia
Primary: Collection of Post-treatment Catheterization for Safety — 2 participants
N/A N=56 Lessening Incontinence Through Low-impact Activity
Urinary Incontinence
Primary: Total Incontinence Frequency — -2.8; -1.9 episodes per day — p=0.13
Phase 4 N=181 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Ureteral Obstruction
Primary: Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion — 1.76; 1.84; 2.02; 1.93 score on a scale
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
N/A N=101 Prostatic Urethral Lift in Subject With Acute Urinary Retention
Acute Urinary Retention · Benign Prostatic Hyperplasia
Primary: Successful Trial Without Catheter Peri-procedurally — 29; 0 Participants
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
Phase 4 N=42 Validation of a Real-time Urodynamic Measure of Urinary Urgency
Overactive Bladder Syndrome
Primary: Change in Maximal Cystometric Capacity (mL) — 95; 473.50 milliliters (mL) — p=.005
N/A N=17 Uterosacral Ligament Suspension Clip
Pelvic Organ Prolapse
Primary: Suture Location in Relation to the Surrounding Anatomy — 2.5; 2.8; 2.2; 2.2 cm
Phase 2 N=315 Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Week 12 — 21.8; 21.5; -6.3; -5.6 Score on a scale
N/A N=51 UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Benign Prostatic Hyperplasia
Primary: Quality of Recovery — 28; 16 participants
N/A N=23 Use of the Leva Incontinence System in Treating Bladder Incontinence.
Stress Urinary Incontinence
Primary: Symptoms of Urinary Incontinence at Baseline and at 6 Weeks — 27.5; 1.1 score on a scale — p=0.0001